| Literature DB >> 33520015 |
Haijun Xiong1, Zhaowei Dong1, Guanhua Lou1, Qingxia Gan1, Jin Wang1, Qinwan Huang1.
Abstract
INTRODUCTION: The novel coronavirus pneumonia that broke out in 2019 has become a global epidemic. According to the diagnosis and treatment plan issued in China and the existing clinical data, Shufeng Jiedu (SFJD) Capsule can be effectively used in the treatment of COVID-19 patients. This study aimed to explore its mechanism of action by network pharmacology and molecular docking technology.Entities:
Keywords: COVID-19; Mechanism; Network pharmacology; Shufeng Jiedu capsule; Traditional Chinese medicine
Year: 2020 PMID: 33520015 PMCID: PMC7836709 DOI: 10.1016/j.eujim.2020.101241
Source DB: PubMed Journal: Eur J Integr Med ISSN: 1876-3820 Impact factor: 1.314
Fig. 1The flow chart of this whole analysis.
Four properties, five flavors and meridians.
| Hu Zhang | Mildly cold | Mildly bitter | Gallbladder meridian, |
| Lian Qiao | Mildly cold | Bitter | Lung meridian, |
| Ban Lan Gen | Cold | Bitter | Stomach meridian, |
| Chai Hu | Mildly cold | Bitter, | Gallbladder meridian, |
| Bai Jiang Cao | Mildly cold | Bitter, | Stomach meridian, |
| Ma Bian Cao | Cold | Bitter, | Liver meridian, |
| Lu Gen | Cold | Sweet | Bladder meridian, |
| Gan Cao | Even | Sweet | Lung meridian, |
Information of some active ingredients of SFJD.
| Ban Lan Gen | MOL001810 | 6-(3-oxoindolin-2-ylidene)indolo[2,1-b]quinazolin-12-one | 97457-31-3 | 45.28 | 0.89 |
| Lian Qiao | MOL000791 | bicuculline | 485-49-4 | 69.67 | 0.88 |
| Gan Cao | MOL005018 | Xambioona | N/A | 54.85 | 0.87 |
| Lian Qiao | MOL003305 | PHILLYRIN | 487-41-2 | 36.4 | 0.86 |
| Lian Qiao | MOL003365 | Lactucasterol | N/A | 40.99 | 0.85 |
| Lian Qiao | MOL000522 | arctiin | 20362-31-6 | 34.45 | 0.84 |
| Ma Bian Cao | MOL008752 | Dihydroverticillatine | N/A | 42.69 | 0.84 |
| Ban Lan Gen | MOL001806 | Stigmasta-5,22-diene-3beta,7beta-diol | N/A | 42.56 | 0.83 |
| Ban Lan Gen | MOL001804 | Stigmasta-5,22-diene-3beta,7alpha-diol | N/A | 43.04 | 0.82 |
| Lian Qiao | MOL003281 | 20(S)-dammar-24-ene-3β,20-diol-3-acetate | N/A | 40.23 | 0.82 |
| Lian Qiao | MOL003315 | 3beta-Acetyl-20,25-epoxydammarane-24alpha-ol | N/A | 33.07 | 0.79 |
| Lian Qiao | MOL000211 | Mairin | 472-15-1 | 55.38 | 0.78 |
| Lian Qiao | MOL000211 | Betulinic Acid | 472-15-1 | 55.38 | 0.78 |
| Gan Cao | MOL000211 | Mairin | 472-15-1 | 55.38 | 0.78 |
| Gan Cao | MOL005001 | Gancaonin H | 126716-35-6 | 50.1 | 0.78 |
| Ban Lan Gen | MOL001755 | 24-Ethylcholest-4-en-3-one | 67392-96-5 | 36.08 | 0.76 |
| Ban Lan Gen | MOL000449 | Stigmasterol | 83-48-7 | 43.83 | 0.76 |
| Chai Hu | MOL000449 | Stigmasterol | 83-48-7 | 43.83 | 0.76 |
| Chai Hu | MOL004718 | α-spinasterol | 481-18-5 | 42.98 | 0.76 |
| Bai Jiang Cao | MOL000449 | Stigmasterol | 83-48-7 | 43.83 | 0.76 |
Fig. 2Venn analysis of genes. (A) Disease-associated genes; (B) Co-targeted genes. NOTE: The original data showed in supplementary material 2.
Fig. 3PPI network.
Analysis of interaction topology parameters of important targets.
| RELA | 24 | 0.23065476 | 0.09948818 | 0.544 |
| MAPK1 | 24 | 0.19791667 | 0.12555263 | 0.53968254 |
| IL6 | 23 | 0.23510467 | 0.11059687 | 0.52713178 |
| MAPK3 | 23 | 0.21661491 | 0.08636058 | 0.53543307 |
| TNF | 23 | 0.21510297 | 0.11857879 | 0.544 |
| TP53 | 19 | 0.22105263 | 0.10271104 | 0.4822695 |
| MAPK8 | 17 | 0.27566321 | 0.0445486 | 0.48920863 |
| MAPK14 | 17 | 0.25860155 | 0.06081331 | 0.5 |
| IL1B | 16 | 0.29211957 | 0.0161661 | 0.46896552 |
| IL2 | 15 | 0.32533333 | 0.01679801 | 0.47887324 |
| NFKB1 | 15 | 0.30068027 | 0.02367776 | 0.47552448 |
| FOS | 15 | 0.28148148 | 0.03306335 | 0.49635036 |
| IL10 | 13 | 0.33679834 | 0.00804039 | 0.42236025 |
| IL4 | 13 | 0.32915921 | 0.01284505 | 0.45033113 |
| STAT1 | 12 | 0.29411765 | 0.02445102 | 0.47552448 |
| IFNG | 11 | 0.35909091 | 0.01944479 | 0.425 |
| CCL2 | 11 | 0.35698448 | 0.00735614 | 0.43312102 |
| INS | 11 | 0.17748918 | 0.15055889 | 0.45637584 |
| IL13 | 10 | 0.4 | 0.00565501 | 0.41212121 |
| LCK | 10 | 0.375 | 0.00134214 | 0.44444444 |
| CASP8 | 10 | 0.35102041 | 0.01572466 | 0.45945946 |
| BCL2L1 | 10 | 0.34324324 | 0.00764597 | 0.40718563 |
| EGFR | 10 | 0.27454545 | 0.03172251 | 0.4822695 |
Fig. 4GO enrichment analysis. (A) Biological process analysis; (B) Molecular function analysis; (C) Cell composition analysis.
The co-targeted genes Reactome pathways enrichment analysis (top10).
| R-HSA-6783783 | Interleukin-10 signaling | 22 | 86 | 0.005861 | 1.11E-16 | 2.04E-14 | 13 | 15 | 0.001157 |
| R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 36 | 211 | 0.01438 | 1.11E-16 | 2.04E-14 | 35 | 46 | 0.003549 |
| R-HSA-449147 | Signaling by Interleukins | 62 | 639 | 0.043549 | 1.11E-16 | 2.04E-14 | 171 | 490 | 0.037803 |
| R-HSA-1280215 | Cytokine Signaling in Immune system | 73 | 1312 | 0.089416 | 1.11E-16 | 2.04E-14 | 239 | 735 | 0.056704 |
| R-HSA-168256 | Immune System | 84 | 2869 | 0.195529 | 1.11E-16 | 2.04E-14 | 330 | 1634 | 0.126061 |
| R-HSA-109606 | Intrinsic Pathway for Apoptosis | 12 | 61 | 0.004157 | 4.88E-13 | 7.52E-11 | 27 | 62 | 0.004783 |
| R-HSA-5660668 | CLEC7A/inflammasome pathway | 6 | 8 | 5.45E-04 | 1.48E-10 | 1.95E-08 | 4 | 4 | 3.09E-04 |
| R-HSA-447115 | Interleukin-12 family signaling | 11 | 96 | 0.006543 | 1.34E-09 | 1.47E-07 | 22 | 114 | 0.008795 |
| R-HSA-8950505 | Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 10 | 73 | 0.004975 | 1.44E-09 | 1.47E-07 | 5 | 36 | 0.002777 |
| R-HSA-2559583 | Cellular Senescence | 14 | 200 | 0.01363 | 3.80E-09 | 3.50E-07 | 39 | 90 | 0.006943 |
Fig. 5Simulation diagram for SFJD treatment. (A) SFJD treatment in the immune system; (B) Cytokine signaling in the immune system (HSA-1280215); (C) Signaling by interleukins (HSA-449147). NOTE: FDR: false discovery rate. Acknowledgment: These pictures were drawn based on the database of Reactome.
Fig. 6TCMATCOV network of ingredient-drug target- disease protein. NOTES: Node size represents the size of the degree (original data showed in supplement material 6). Blue dots indicate Disease Protein, red dots indicate Drug Target, orange boxes indicate Disease specific cytokine, and green triangles indicate Ingredient. NOTES: BXTM: Ban Xia Tian Ma Bai Zhu Tang; HSZF: Han Shi Zu Fei Tang.
SFJD (herbs) and related TCM prescriptions validation results by TCMATCOV platform.
| Negative Control (BXTM) | 12.59 | -1.84 | 3.53 | -0.76 | -6.46 |
| Positive Control (HSZF) | 20.85 | -4.09 | 9.01 | -1.12 | -6.63 |
| SFJD | 20.84 | -4.05 | 9.28 | -1.19 | -6.33 |
| Hu Zhang | 16.36 | -4.65 | 2.87 | -4.89 | -3.95 |
| Lian Qiao | 8.79 | -2.10 | -0.21 | -0.45 | -6.45 |
| Ban Lan Gen | 18.04 | -4.81 | 5.94 | -1.09 | -6.21 |
| Chai Hu | 16.88 | -2.60 | 7.47 | -1.13 | -5.68 |
Information of core target genes.
| IL-10 | Interleukin 10 | Quercetin; | Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
| TNF | Tumor Necrosis Factor | Quercetin; | Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
| IL-6 | Interleukin 6 | Quercetin; | Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
| IL-2 | Interleukin 2 | Quercetin; | Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
| CCL2 | C-C Motif Chemokine Ligand 2 | Quercetin; | Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
| STAT1 | Signal transducer and activator of transcription 1-alpha/beta | Quercetin; | Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
| IFNG | Interferon gamma | Quercetin; | Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
| CXCL10 | C-X-C motif chemokine 10 | Quercetin; | Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
Fig. 7Molecular docking results. (A) STAT1+Quercetin. (B) TNF+Quercetin. (C) STAT1+Luteolin. (D) IL2+Luteolin. (E) CCL2+Wogonin. (F) TNF+Wogonin. (G) IL10+Kaempferol. (H) IL6+Kaempferol. NOTES: Yellow represents chemical molecules, blue represents sites for docking proteins, and green represents proteins.
| Quercetin | TNF (5M2J) | -4.82 | 5 |
| Quercetin | STAT1 (2KA6) | -4.6 | 2 |
| Luteolin | IL2 (5LQB) | -5.2 | 4 |
| Luteolin | STAT1 (2KA6) | -5.55 | 1 |
| Wogonin | TNF (5M2J) | -4.9 | 1 |
| Wogonin | CCL2 (4R8I) | -5.26 | 3 |
| Kaempferol | IL10 (1LK3) | -5.48 | 4 |
| Kaempferol | IL6 (5FUC) | -5.32 | 3 |
Comparison of network pharmacological analysis of different traditional Chinese medicines for COVID-19.
| ShuFeng JieDu capsule | TCMSP; | Key targets: RELA, MAPK1, MAPK14, CASP3, CASP8 and IL6. | |
| Huashi Baidu formula | TCMSP; | Key targets: MAPK3, MAPK8, TP53, CASP3, IL6, TNF, MAPK1, CCL2, PTGS2, etc. | |
| Toujie Quwen granule | TCMSP; | Key active ingredients: umbelliprenin, quercetin, kaempferol, luteolin, praeruptorin E, stigmasterol, and oroxylin A. | |
| Ma Xing Shi Gan Decoction | TCMSP; | Key targets: HSP90, AKT1, JUN, MAPK1, TP53, ESR1, VEGFA, and TNF. | |
| Qing-Fei-Pai-Du decoction | UHPLC-Q-Orbitrap HRMS; | Key active ingredients: baicalin, glycyrrhizic acid, hesperidin, and hyperoside. | |
| Lian Hua Qing Wen | TCMSP; | KEGG signaling pathways: cancer, immune system-, and viral infection diseases. | |
| Maxingyigan Decoction | TCMSP; | Molecular docking: Quercetin/Formononetin/Luteolin+ IL6/ CASP3/ IL4/ SARS-CoV-2. | |
| Cold-Damp Plague Formula | TCMSP; | Key targets: IL6, TNF, IL10, MAPK8, MAPK3, CXCL8, CASP3, PTGS2, TP53, and MAPK1. | |
| Respiratory Detox Shot | TCMSP; | Molecular docking: One-hundred and eighteen candidate constituents showed a high binding affinity with SARS-coronavirus-2 3-chymotrypsin-like protease (3CLpro). | |
| Rhizoma Polygonati | TCMSP; | Key active ingredients: diosgenin, 3′-Methoxydaidzein, 4′,5-Dihydroxyflavone, (2R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-one, , DFV, Lopinavir, Remdesivir, (+)-Syringaresinol-O-beta-D-glucoside, beta-sitosterol, sitosterol, baicalein, methylprotodioscin_qt. |